As of June 30, 2026, ABIONYX Pharma SA carries a market capitalization of 87.97M, placing it among publicly traded companies globally. Its enterprise value stands at 62.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 87.97M |
| Enterprise Value | 62.74M |
ABIONYX Pharma SA's next confirmed earnings release is scheduled for March 16, 2027.
| Earnings Date | 3/16/2027 |
As of June 30, 2026, ABIONYX Pharma SA has 42.29M shares outstanding.
| Shares Outstanding | 42.29M |
These figures are as of June 30, 2026.
| PB Ratio | 5.58 |
| P/TBV Ratio | 8.51 |
As of June 30, 2026, ABIONYX Pharma SA maintains a current ratio of 5.03, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.03 |
| Quick Ratio | 4.61 |
| Debt / Equity | 10.38 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 49.00 |
As of the close on November 17, 2026, ABIONYX Pharma SA's stock has declined approximately 59.73% over the past 52 weeks. The 50-day moving average sits at 1.67, while the 200-day moving average is 2.51.
| 52-Week Price Change | -59.73% |
| 50-Day Moving Average | 1.67 |
| 200-Day Moving Average | 2.51 |
As of June 30, 2026, ABIONYX Pharma SA holds 26.87M in cash and equivalents against 1.64M in total debt, resulting in a net debt position of -26.44M. Total book value stands at 15.78M, with working capital of 23.51M providing operational flexibility.
| Cash & Cash Equivalents | 26.87M |
| Total Debt | 1.64M |
| Net Debt | -26.44M |
| Equity (Book Value) | 15.78M |
| Book Value Per Share | 0.37 |
| Working Capital | 23.51M |
ABIONYX Pharma SA's most recent stock split took place on May 29, 2026 with a 65:66 split ratio.
| Last Split Date | 5/29/2026 |
| Split Ratio | 65:66 |
Already premium?